{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:17:04Z","timestamp":1783163824163,"version":"3.54.6"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40261-026-01561-z","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:58:23Z","timestamp":1778903903000},"page":"733-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Completeness of Adverse Event Reporting in Clinical Trials of Psoriasis Treatments: A Registry\u2013Publication Comparison Study"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9522-3595","authenticated-orcid":false,"given":"Madeline","family":"Rowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellen","family":"Keefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hazlitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elghzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia Ito","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Vassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"1","key":"1561_CR1","doi-asserted-by":"publisher","first-page":"15528","DOI":"10.1038\/s41598-025-99075-9","volume":"15","author":"E Ntawuyamara","year":"2025","unstructured":"Ntawuyamara E, Deng B, Liang Y. Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study. Sci Rep. 2025;15(1):15528.","journal-title":"Sci Rep"},{"issue":"1","key":"1561_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","volume":"8","author":"J Guo","year":"2023","unstructured":"Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8(1):437.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1561_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.311","volume":"41","author":"RP Nair","year":"2009","unstructured":"Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009;41(2):199\u2013204.","journal-title":"Nat Genet"},{"issue":"11","key":"1561_CR4","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ng.688","volume":"42","author":"U H\u00fcffmeier","year":"2010","unstructured":"H\u00fcffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet. 2010;42(11):996\u20139.","journal-title":"Nat Genet"},{"issue":"2","key":"1561_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/511051","volume":"80","author":"M Cargill","year":"2007","unstructured":"Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273\u201390.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"1561_CR6","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1038\/sj.jid.5701255","volume":"128","author":"RP Nair","year":"2008","unstructured":"Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128(7):1653\u201361.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1561_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/ijd.13236","volume":"55","author":"B Strober","year":"2016","unstructured":"Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016;55(4):401\u20137.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1561_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"10370","key":"1561_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola JF, Landew\u00e9 R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38\u201348.","journal-title":"Lancet"},{"issue":"2","key":"1561_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CEM Griffiths","year":"2010","unstructured":"Griffiths CEM, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"1561_CR11","first-page":"278","volume":"63","author":"WB Kim","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278\u201385.","journal-title":"Can Fam Physician"},{"issue":"11","key":"1561_CR12","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s13555-023-01024-9","volume":"13","author":"MC Fargnoli","year":"2023","unstructured":"Fargnoli MC, De Simone C, Gisondi P, Pellacani G, Calzavara-Pinton P. Topical treatment for the management of mild-to-moderate psoriasis: a critical appraisal of the current literature. Dermatol Ther (Heidelb). 2023;13(11):2527\u201347.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1561_CR13","unstructured":"Psoriasis [Internet]. [cited 2025 Jul 7]. https:\/\/www.mayoclinic.org\/diseases-conditions\/psoriasis\/diagnosis-treatment\/drc-20355845."},{"issue":"4","key":"1561_CR14","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1561_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007675","volume":"12","author":"ST Chen","year":"2024","unstructured":"Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, et al. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy. J Immunother Cancer. 2024;12(4):e007675.","journal-title":"J Immunother Cancer"},{"key":"1561_CR16","unstructured":"How long will I have to treat my psoriasis? [Internet]. [cited 2025 Jul 7]. https:\/\/www.aad.org\/public\/diseases\/psoriasis\/treatment\/medications\/how-long."},{"issue":"1","key":"1561_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12874-025-02486-5","volume":"25","author":"N Boyne","year":"2025","unstructured":"Boyne N, Duke A, Rea J, Khan A, Young A, Van Vleet J, et al. Discrepancies in safety reporting for chronic back pain clinical trials: an observational study from ClinicalTrials.gov and publications. BMC Med Res Methodol. 2025;25(1):33.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"1561_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1200\/JCO.2013.52.2219","volume":"32","author":"S Sivendran","year":"2014","unstructured":"Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, et al. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014;32(2):83\u20139.","journal-title":"J Clin Oncol"},{"key":"1561_CR19","unstructured":"ClinicalTrials.gov [Internet]. [cited 2025 Jul 7]. https:\/\/clinicaltrials.gov\/policy\/fdaaa-801-final-rule."},{"key":"1561_CR20","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 [cited 2024 Jun 18];372. https:\/\/www.bmj.com\/content\/372\/bmj.n71."},{"key":"1561_CR21","unstructured":"Office for Human Research Protections (OHRP). HHS.gov. US Department of Health and Human Services; 2016 [cited 2024 Jun 19]. 45 CFR 46. https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/regulations\/45-cfr-46\/index.html."},{"key":"1561_CR22","unstructured":"PROSPERO [Internet]. [cited 2025 Jul 25]. https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251081207."},{"key":"1561_CR23","unstructured":"42 CFR part 11\u2014Clinical trials registration and results information submission [Internet]. [cited 2025 Jul 24]. https:\/\/www.ecfr.gov\/current\/title-42\/chapter-I\/subchapter-A\/part-11."},{"key":"1561_CR24","unstructured":"ClinicalTrials.gov [Internet]. [cited 2025 Jul 8]. https:\/\/clinicaltrials.gov\/find-studies\/constructing-complex-search-queries#expansionOp."},{"key":"1561_CR25","unstructured":"OSF - Psoriasis Adverse Event Reporting [Internet]. [cited 2025 Jul 24]. https:\/\/osf.io\/4jaz3\/?view_only=4d0f4e76c15646dab34c53f41722e0f4."},{"issue":"9","key":"1561_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031138","volume":"9","author":"EK Wong","year":"2019","unstructured":"Wong EK, Lachance CC, Page MJ, Watt J, Veroniki A, Straus SE, et al. Selective reporting bias in randomised controlled trials from two network meta-analyses: comparison of clinical trial registrations and their respective publications. BMJ Open. 2019;9(9):e031138.","journal-title":"BMJ Open"},{"issue":"1","key":"1561_CR27","doi-asserted-by":"publisher","first-page":"27762","DOI":"10.1038\/s41598-024-79394-z","volume":"14","author":"A Kre\u0161o","year":"2024","unstructured":"Kre\u0161o A, Grahovac M, Znaor L, Maru\u0161i\u0107 A. Safety reporting in trials on glaucoma interventions registered in ClinicalTrials.gov and corresponding publications. Sci Rep. 2024;14(1):27762.","journal-title":"Sci Rep"},{"key":"1561_CR28","unstructured":"Checklist for evaluating whether a clinical trial or study is an applicable clinical trial (ACT) [Internet]. [cited 2025 Jul 8]. https:\/\/cdn.clinicaltrials.gov\/documents\/ACT_Checklist.pdf."},{"key":"1561_CR29","unstructured":"Elaboration of definitions of responsible party and applicable clinical trial [Internet]. https:\/\/cdn.clinicaltrials.gov\/documents\/ElaborationsOnDefinitions.pdf."},{"key":"1561_CR30","unstructured":"21 USC 360bbb-3a: Emergency use of medical products [Internet]. [cited 2025 Jul 23]. https:\/\/uscode.house.gov\/view.xhtml?req=granuleid:USC-prelim-title21-section360bbb-3a&num=0&edition=prelim."},{"key":"1561_CR31","unstructured":"42 CFR 11.48\u2014what constitutes clinical trial results information? [Internet]. [cited 2025 Jul 24]. https:\/\/www.ecfr.gov\/current\/title-42\/chapter-I\/subchapter-A\/part-11\/subpart-C\/section-11.48."},{"issue":"9","key":"1561_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002127","volume":"13","author":"S Golder","year":"2016","unstructured":"Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. PLoS Med. 2016;13(9):e1002127.","journal-title":"PLoS Med"},{"key":"1561_CR33","doi-asserted-by":"publisher","DOI":"10.7326\/M13-0480","author":"D Hartung","year":"2014","unstructured":"Hartung D, Zarin DA, Guise JM, Mcdonagh M, Paynter R, Helfand M. Reporting discrepancies between the ClinicalTrials.gov results database and peer reviewed publications. 2014. Ann Intern Med. https:\/\/doi.org\/10.7326\/M13-0480."},{"key":"1561_CR34","unstructured":"Python.org [Internet]. 2025 [cited 2025 Jul 25]. Python Software Foundation. Python [Internet]. https:\/\/www.python.org\/."},{"key":"1561_CR35","unstructured":"The R Project for Statistical Computing [Internet] [Internet]. [cited 2025 Jul 25]. https:\/\/www.r-project.org\/."},{"key":"1561_CR36","unstructured":"Posit [Internet]. [cited 2025 Jul 25]. Posit team. RStudio: Integrated Development Environment for R.Posit Software, PBC, Boston, MA [Internet]. 2025. https:\/\/posit.co\/."},{"key":"1561_CR37","unstructured":"PROSPERO [Internet]. [cited 2025 Jul 7]. https:\/\/www.crd.york.ac.uk\/PROSPERO\/home."},{"key":"1561_CR38","unstructured":"OSF [Internet]. [cited 2025 Jul 7]. https:\/\/osf.io\/."},{"issue":"1","key":"1561_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12916-015-0430-4","volume":"13","author":"E Tang","year":"2015","unstructured":"Tang E, Ravaud P, Riveros C, Perrodeau E, Dechartres A. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. BMC Med. 2015;13(1):189.","journal-title":"BMC Med"},{"issue":"1","key":"1561_CR40","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12874-022-01730-6","volume":"22","author":"I Paladin","year":"2022","unstructured":"Paladin I, Prani\u0107 SM. Reporting of the safety from allergic rhinitis trials registered on ClinicalTrials.gov and in publications: an observational study. BMC Med Res Methodol. 2022;22(1):262.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"1561_CR41","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/jce.16682","volume":"36","author":"V Li\u0161ni\u0107","year":"2025","unstructured":"Li\u0161ni\u0107 V, \u0160aler F, Vi\u0111ak M, Maru\u0161i\u0107 A. Safety reporting in trials on atrial fibrillation: an observational study of ClinicalTrials.Gov registry and corresponding publications. J Cardiovasc Electrophysiol. 2025;36(6):1377\u201385.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1561_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.02.144","author":"Z Song","year":"2025","unstructured":"Song Z, Pymento J, Bortoluzzi T, Vyas MV, Uleryk EM, Chan AW. Evaluating adverse event reporting in parallel-group randomized trials published in dermatology-specific journals: a methodological systematic review. J Invest Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jid.2025.02.144.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"1561_CR43","doi-asserted-by":"publisher","first-page":"204209862093859","DOI":"10.1177\/2042098620938595","volume":"10","author":"M Alomar","year":"2020","unstructured":"Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020;10(11):2042098620938595.","journal-title":"Ther Adv Drug Saf."},{"issue":"2","key":"1561_CR44","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3163\/1536-5050.95.2.224","volume":"95","author":"V Craigle","year":"2007","unstructured":"Craigle V. MedWatch: the FDA safety information and adverse event reporting program. J Med Libr Assoc. 2007;95(2):224\u20135.","journal-title":"J Med Libr Assoc"},{"key":"1561_CR45","unstructured":"Office of the Commissioner. US Food and Drug Administration. FDA; 2024 [cited 2025 Jul 17]. MedWatch: the FDA Safety Information and Adverse Event Reporting Program. https:\/\/www.fda.gov\/safety\/medwatch-fda-safety-information-and-adverse-event-reporting-program."},{"issue":"8","key":"1561_CR46","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1001\/jamainternmed.2017.2762","volume":"177","author":"M Kwa","year":"2017","unstructured":"Kwa M, Welty LJ, Xu S. Adverse events reported to the US food and drug administration for cosmetics and personal care products. JAMA Intern Med. 2017;177(8):1202\u20134.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"1561_CR47","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11606-018-4779-x","volume":"34","author":"JD Wallach","year":"2019","unstructured":"Wallach JD, Egilman AC, Ross JS, Woloshin S, Schwartz LM. Timeliness of postmarket studies for new pharmaceuticals approved between 2009 and 2012: a cross-sectional analysis. J Gen Intern Med. 2019;34(4):492\u20135.","journal-title":"J Gen Intern Med"},{"issue":"12","key":"1561_CR48","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/pds.4196","volume":"26","author":"JC Bouvy","year":"2017","unstructured":"Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005\u20132013. Pharmacoepidemiol Drug Saf. 2017;26(12):1442\u201350.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"1561_CR49","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00403-006-0707-8","volume":"298","author":"U Mrowietz","year":"2006","unstructured":"Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Derm Res. 2006;298(7):309\u201319.","journal-title":"Arch Derm Res."},{"issue":"3","key":"1561_CR50","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s43441-019-00107-0","volume":"54","author":"J Ganju","year":"2020","unstructured":"Ganju J. Improving the standards of reporting of clinical trial data. Ther Innov Regul Sci. 2020;54(3):717\u201322.","journal-title":"Ther Innov Regul Sci."},{"issue":"9","key":"1561_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003436","volume":"3","author":"A Hodkinson","year":"2013","unstructured":"Hodkinson A, Kirkham JJ, Tudur-Smith C, Gamble C. Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open. 2013;3(9):e003436.","journal-title":"BMJ Open"},{"issue":"Suppl 2","key":"1561_CR52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12859-019-2628-5","volume":"20","author":"L Wu","year":"2019","unstructured":"Wu L, Ingle T, Liu Z, Zhao-Wong A, Harris S, Thakkar S, et al. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA. BMC Bioinform. 2019;20(Suppl 2):97.","journal-title":"BMC Bioinform"},{"issue":"4","key":"1561_CR53","first-page":"509","volume":"18","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010;18(4):509\u201322.","journal-title":"Support Care Cancer"},{"key":"1561_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/9781118590638.ch5","volume-title":"Dermatologic principles and practice in oncology","author":"A Chen","year":"2013","unstructured":"Chen A, Acharya A, Setser A. Grading dermatologic adverse events in clinical trials using CTCAE v4.0. In: Dermatologic principles and practice in oncology. Oxford: Wiley; 2013. p. 47\u201359."},{"key":"1561_CR55","unstructured":"Asdsa launches new patient safety database gathering adverse events during dermatologic surgery procedures [Internet]. [cited 2025 Jul 23]. https:\/\/www.asds.net\/skin-experts\/news-room\/press-releases\/asdsa-launches-new-patient-safety-database-gathering-adverse-events-during-dermatologic-surgery-procedures."},{"issue":"10","key":"1561_CR56","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00403-021-02265-4","volume":"314","author":"BY Kang","year":"2022","unstructured":"Kang BY, Ibrahim SA, Poon E, Hellquist K, Avram MM, Alam M. The cutaneous procedures adverse events reporting (CAPER) registry. Arch Dermatol Res. 2022;314(10):987\u20139.","journal-title":"Arch Dermatol Res"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01561-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:29:43Z","timestamp":1783160983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01561-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1561"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01561-z","relation":{"references":[{"id-type":"doi","id":"10.7326\/M13-0480","asserted-by":"subject"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Abstract and\nrunning head have been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.V. reports receipt of funding from the National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, the US Office of Research Integrity, Oklahoma Center for Advancement of Science and Technology, and internal grants from Oklahoma State University Center for Health Sciences\u2014all outside of the present work. A.F. reports funding from the Center for Integrative Research on Childhood Adversity, Oklahoma Shared Clinical and Translational Resources, and internal Oklahoma State University Center for Health Sciences grants, all outside this work. All other authors have no competing interests to declare that are relevant to the content of this article. All other authors have nothing to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Madeline Rowe and Madison Dinh contributed to data curation, performing all data extraction and assisting in writing\u2014original draft preparation. Ryan Sherry, Kellen Keefer, Rachel Hazlitt, Ahmed Elghzali, Tag Harris, Logan Corwin, and Daniel Archer were responsible for methodology, including drafting the protocol, submitting IRB documents, guiding data extraction decisions, interpreting results, providing project administration, and writing\u2014review and editing. Daniel Archer and Tag Harris also conducted formal analysis, including generating tables and figures. Alicia Ito Ford contributed to the conceptualization, investigation, supervision, and writing\u2014review and editing; supported student training; and resolved methodological queries. Matt Vassar led the conceptualization, supervision, and project administration, provided student training, and contributed to writing\u2014original draft and writing\u2014review and editing. All authors meet ICMJE authorship criteria and agree to be accountable for all aspects of the work. Authors have read and have approved the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The Oklahoma State University Center for Health Sciences Institutional Review Board determined this study did not meet the definition of human subjects research and was exempt from oversight under 45 CFR 46.102(d) and (f).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The datasets generated during and\/or analyzed during the current study are available in the Open Science Framework (OSF) repository (\n                      \n                      ). All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}